Welcome to our dedicated page for Evolent Health SEC filings (Ticker: EVH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Evolent Health filings document the regulatory disclosures of a healthcare services company focused on complex specialty care and value-based care infrastructure. Its 8-K reports cover operating and financial results, material agreements, capital-structure matters, completed subsidiary transactions, and compensation arrangements tied to executive appointments.
Proxy materials disclose annual meeting matters, board oversight, director elections, executive compensation, and governance practices. Other current reports record board and officer transitions, equity incentives, and corporate events affecting Evolent Health, Inc. and its wholly owned subsidiary structure.
Ramos Mario reported acquisition or exercise transactions in this Form 4 filing.
Evolent Health, Inc. Chief Financial Officer Mario Ramos received a grant of 429,041 performance-based share units (PSUs) at a price of $0.00 per unit. The PSUs are granted under the company’s Amended and Restated 2015 Omnibus Incentive Compensation Plan and may be earned based on stock price performance between March 1, 2027 and February 28, 2029, subject to service-based conditions. Each PSU is currently shown at a target level, and the final number earned can range from 0% to 250% of this target after the performance period.
Evolent Health, Inc. reports on its value-based healthcare services business, which focuses on managing complex specialty care such as oncology, cardiology and musculoskeletal conditions for health plans and other risk-bearing entities. The company designs evidence-based clinical pathways, builds high-performance provider networks and uses proprietary technology platforms, including Identifi®, to support clinical decisions and administrative services.
Revenue comes mainly from per-member-per-month fees under specialty care management and administrative services contracts, with some performance-based and capitated arrangements where Evolent shares financial risk for medical costs. The company highlights reliance on a few large partners, growing use of risk-sharing contracts, regulatory exposure in Medicare and Medicaid, and extensive fraud, privacy, AI and data-security compliance requirements as key risks.
Evolent Health reported weaker 2025 GAAP results but stable adjusted profitability and set cautious 2026 targets. Full-year 2025 revenue was $1.88 billion, down from $2.55 billion in 2024, while net loss widened to $579.4 million with a net loss margin of 30.9%.
Results were heavily impacted by a $398 million goodwill impairment, a $52.5 million loss on option exercise and refinancing-related charges. By contrast, adjusted EBITDA was $151.2 million with an 8.1% margin, up from a 6.3% margin in 2024, and adjusted income attributable to common shareholders was $10.4 million.
Management forecast 2026 revenue of $2.4–$2.6 billion and adjusted EBITDA of $110–$140 million, implying strong top-line growth but lower adjusted EBITDA than 2025 as new Performance Suite contracts and health-plan membership shifts pressure margins early in the year.
Evolent Health, Inc. received an amended ownership report from Eventide Asset Management, LLC and individuals Finny Kuruvilla and Robin C. John. They report beneficial ownership of 1,713 shares of Class A common stock, representing 0.0% of the class as of 12/31/2025.
Eventide holds sole voting and dispositive power over the 1,713 shares, while Kuruvilla and John share voting and dispositive power over the same shares. The securities are certified as acquired and held in the ordinary course of business and not for the purpose of influencing control of Evolent Health.
Morgan Stanley has updated its ownership disclosure in Evolent Health, Inc. through an amended Schedule 13G. As of the event date of 12/31/2025, Morgan Stanley reports beneficial ownership of 9,097,808 shares of Evolent’s Class A common stock, representing 8.1% of the class. Its affiliate Morgan Stanley Capital Services LLC reports beneficial ownership of 7,380,233 shares, or 6.6% of the class.
The firms report shared voting and dispositive power over these shares and confirm the holdings were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Evolent Health. Certain other Morgan Stanley units with disaggregated reporting are expressly excluded from this disclosure.
FMR LLC and Abigail P. Johnson filed an amended Schedule 13G reporting their beneficial ownership of Evolent Health’s Class A common stock as of 12/31/2025. They report beneficial ownership of 750,886.96 shares, representing 0.7% of the outstanding Class A common stock.
FMR LLC has sole voting power over 741,735.20 shares and sole dispositive power over 750,886.96 shares. Abigail P. Johnson reports sole dispositive power over 750,886.96 shares with no voting power. The securities are certified as held in the ordinary course of business and not for the purpose of changing or influencing control of Evolent Health.
The Vanguard Group filed an amended Schedule 13G showing beneficial ownership of 8,914,065 shares of Evolent Health Inc common stock, representing 7.98% of the class as of 12/31/2025. Vanguard reports shared voting power over 933,846 shares and shared dispositive power over all 8,914,065 shares, with no sole voting or dispositive power.
The filing explains that Vanguard’s clients, including registered investment companies and other managed accounts, have the economic rights to dividends and sale proceeds, with no single client holding more than 5% of the class. Vanguard notes an internal realignment effective January 12, 2026, after which certain subsidiaries are expected to report holdings separately. Vanguard certifies the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of Evolent Health.
Evolent Health, Inc. reported that director Ms. Smith received an equity award of 23,137 restricted stock units of Class A common stock on 01/02/2026. The units were granted at a price of $0 under the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan and are shown as directly owned after the transaction.
The restricted stock units vest on the earlier of January 2, 2027 or the date of the company’s 2026 annual meeting, as long as she continues in service through the vesting date.
Evolent Health, Inc. reported that its Chief Financial Officer received a special one-time restricted stock unit (RSU) grant. On 01/02/2026, the officer acquired 587,500 RSUs for Class A Common Stock at a price of $0 per unit, recorded as a direct holding. The grant was made as an employment inducement award under Rule 303A.08 of the New York Stock Exchange Listing Manual.
The RSUs vest over three years, with 34% scheduled to vest on January 2, 2027 and 33% on each of January 2, 2028 and January 2, 2029, subject to the executive’s continued employment through each vesting date. Upon vesting, each unit converts into one share of Class A Common Stock, aligning the CFO’s compensation more closely with the company’s equity performance.
Evolent Health, Inc. filed an initial insider ownership report for its Chief Financial Officer. The filing shows that, as of the event date of January 2, 2026, the CFO reported beneficial ownership of 0 shares of Class A common stock, held directly. The report also indicates no derivative securities, such as options or warrants, reported as beneficially owned. The form is filed as a single-reporting-person filing and references a Power of Attorney dated December 12, 2025 authorizing execution of the document.